A potential issue associated with the clinical application of IL-2Rα that covalently binds to IL-2 for the treatment of AD is the ability of Teffs to upregulate IL-2Rα,6,18 although this usually requires robust activation. The gene discussed is IL2; the disease is Alzheimer disease.